Impact of Angiotensin I-converting Enzyme Inhibitors and Angiotensin II Type-1 Receptor Blockers on Survival of Patients with NSCLC

Lili Miao¹,²,⁎, Wei Chen¹,⁎, Ling Zhou¹, Huanying Wan¹, Beili Gao¹ & Yun Feng¹

It has been shown that angiotensin I-converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor blockers (ARBs) can decrease tumor growth and tumor-associated angiogenesis and inhibit metastasis. Epidermal growth factor receptor (EGFR) mutations are found in approximately 30% of patients with advanced non-small cell lung cancer (NSCLC) in East Asia and in 10–15% of such patients in Western countries. We retrospectively identified 228 patients with histologically confirmed advanced NSCLC and 73 patients with early stage disease; 103 of these patients took antihypertensive drugs, and 112 received treatment with EGFR tyrosine kinase inhibitors (TKIs). There was a significant difference in progression-free survival after first-line therapy (PFS1) between the ACEI/ARB group and the non-ACEI/ARB group. For the patients treated with TKIs, there was a significant difference in PFS but not in overall survival (OS) between the ACEI/ARB group and the non-ACEI/ARB group. For the patients with advanced NSCLC, there was a significant difference in PFS1 between the ACEI/ARB group and the non-ACEI/ARB group. ACEI/ARB in combination with standard chemotherapy or TKIs had a positive effect on PFS1 or OS, regardless of whether the lung cancer was in the early or advanced stage.

Lung cancer causes 1.4 million deaths per year worldwide. The 5-year survival rate of patients with advanced-stage (inoperable) non-small cell lung cancer (NSCLC) is 18%, with a median survival of 6–12 months. The main treatments for NSCLC are surgery, chemotherapy, targeted therapy and immunotherapy.

Angiotensin I-converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor blockers (ARBs) are the most widely used antihypertensive drugs. The renin-angiotensin system (RAS) is involved in the regulation of arterial pressure. Large epidemiological studies have revealed potentially protective effects of RAS against cancer1,2, although some of the results remain controversial3–8. The local RAS reportedly induces angiogenesis and tumor proliferation by promoting vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR) expression9,10. Angiotensin II, which is a growth factor, has been shown to stimulate tumor growth11,12. ACEIs suppress the local RAS by reducing the production of angiotensin II, whereas ARBs selectively block the action of angiotensin II type-1 receptor (AT1R). Previous studies have suggested that ACEIs and ARBs might decrease tumor growth and tumor-associated angiogenesis and inhibit metastasis13,14. It has been reported that overexpression of angiotensin II-converting enzyme (ACE2) inhibits lung cancer proliferation and angiogenesis15. Recent studies reported that the use of ACEIs or ARBs was associated with longer overall survival (OS) in patients with advanced gastric cancer or lung cancer who received combination chemotherapy as first-line treatment16. Studies have reported reduced rates of distant metastasis and decreased mortality risk in ACEI or ARB users with prostate, colorectal or breast cancer17–19. Approximately 30% of patients with advanced NSCLC in East Asia harbor EGFR mutations. However, there have been no relevant studies of Asian NSCLC patients, particularly those receiving TKIs. We therefore conducted a retrospective study to identify the role of RAS inhibition in the outcomes of patients with NSCLC in China. Moreover, we also examined the influence of ACEIs/ARBs in NSCLC patients receiving TKIs.

¹Department of Respiration, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. ²Department of Respiration, YiZheng People’s Hospital, Jiangsu, China. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to H.W. email: (huanyingwanruijin@126.com) or B.G. email: (yshu7661@sina.com) or Y.F. email: (fy01057@163.com)
Patients and Methods

Ethics. The study protocol was approved by the Coordinating Ethics Committee of Ruijin Hospital. We confirmed that informed consent was obtained from all subjects, and the study methods were conducted in accordance with the approved guidelines.

Patient and clinical data. We retrospectively identified 228 patients with histologically confirmed advanced NSCLC (stage IIIb or IV) and 73 patients with confirmed stage I, II or IIIa disease who presented at our hospital between January 2000 and December 2014 and received at least one cycle of first-line platinum-based chemotherapy. Among these patients, 73 with stage I, II or IIIa disease underwent surgery before chemotherapy. The hospital's electronic database contains all of the individual results of any laboratory test during in- or outpatient care administered by our hospital, together with detailed data on drugs, the doses and timing of any administered chemotherapy and hospital discharge reports, including complete medication records beyond antineoplastic chemotherapy. Performance status was recorded for each patient. Follow-up data were extracted from the patients' records. In addition to the use of ACEIs or ARBs, additional administration of β-blockers, calcium antagonists, and other antihypertensive drugs was noted. Overall, 112 patients were treated with TKIs (gefitinib, erlotinib or icotinib), either as initial therapy and in combination with chemotherapy. The characteristics of the patients treated with EGFR-TKIs are shown in supplementary table 1, and those of the other patients are shown in supplementary table 2.

Statistical analysis. The treatment outcomes were OS and progression-free survival in first-line therapy (PFS1). Survival was calculated from the first day of first-line platinum-based chemotherapy until patient death or last visit. The efficacy analysis was based on the intent-to-treat population. OS was defined as the time between the date of diagnosis of recurrent or metastatic disease and the date of death from any cause. Progression-free survival (PFS) was defined as the time from the date of diagnosis of recurrent or metastatic disease to the date of disease progression or death from any cause. The Kaplan-Meier method was employed to estimate the probability of survival, and survival differences were analyzed using the log-rank test. The χ² test or Fisher’s exact test was used to compare categorical variables. All reported p values were the results of two-sided tests, and p < 0.05 was considered statistically significant. Statistical analyses were performed using SPSS, version 19.0 (Chicago, IL, USA).

Results

Patient characteristics. Between January 2000 and December 2014, 228 patients with advanced NSCLC were treated with platinum-based first-line chemotherapy in our hospital, and another 73 patients with confirmed stage I, II or IIIa disease underwent surgery before adjuvant chemotherapy. Table 1 shows the characteristics of the ACEI/ARB group (n = 52) and the non-ACEI/ARB group (n = 249). There were 112 patients who received sequential treatment with TKIs. The baseline characteristics were generally the same in the ACEI/ARB and non-ACEI/ARB groups. The characteristics of particular patient subgroups, including advanced NSCLC patients, patients who underwent surgery and EGFR-TKI-treated patients, are shown in supplementary table 1, and those of the other patients are shown in supplementary table 2.

Statistical analysis. The treatment outcomes were OS and progression-free survival in first-line therapy (PFS1). Survival was calculated from the first day of first-line platinum-based chemotherapy until patient death or last visit. The efficacy analysis was based on the intent-to-treat population. OS was defined as the time between the date of diagnosis of recurrent or metastatic disease and the date of death from any cause. Progression-free survival (PFS) was defined as the time from the date of diagnosis of recurrent or metastatic disease to the date of disease progression or death from any cause. The Kaplan-Meier method was employed to estimate the probability of survival, and survival differences were analyzed using the log-rank test. The χ² test or Fisher’s exact test was used to compare categorical variables. All reported p values were the results of two-sided tests, and p < 0.05 was considered statistically significant. Statistical analyses were performed using SPSS, version 19.0 (Chicago, IL, USA).

Influence of ACEIs/ARBs on all patients. We assessed the possible impact of long-term medication with ACEIs or ARBs on survival. Among all 301 patients, there was a significant difference in PFS1 between the ACEI/ARB group and the non-ACEI/ARB group (p = 0.002, Fig. 1B). Recipients of either ACEIs or ARBs had a median...
PFS1 that was 2.4 months longer than that of non-recipients in our Kaplan-Meier analysis (9.2 vs. 6.8 months, \( p = 0.002 \), log-rank test). However, there was no significant difference in OS between the ACEI/ARB group and the non-ACEI/ARB group (Fig. 1A).

Influence of ACEIs/ARBs on patients taking TKIs. For the 112 patients taking TKIs, there was a significant difference in PFS between the ACEI/ARB group and the non-ACEI/ARB group (\( p = 0.044 \), Fig. 2B). Recipients of either ACEIs or ARBs had a median PFS that was 3.2 months longer than that of non-recipients in our Kaplan-Meier analysis (11.2 vs. 8.0 months, \( p = 0.044 \), log-rank test). There was no significant difference in OS between the two groups (\( p = 0.095 \), Fig. 2A).

Influence of ACEIs/ARBs on patients who underwent surgery. For the 73 patients with stage I, II or IIIa disease who underwent surgery before chemotherapy, there was no significant difference in OS or PFS between the ACEI/ARB group and the non-ACEI/ARB group (Fig. 3A,B).

There were 23 patients taking antihypertensive drugs. For these 23 patients, there was a significant difference in OS between those taking ACEIs/ARBs and those taking other antihypertensive drugs (\( p = 0.01 \), Fig. 3C). There was no significant difference in PFS1 between the two groups (Fig. 3D).

Influence of ACEIs/ARBs on patients with advanced NSCLC. We examined 228 patients with advanced NSCLC who were treated with platinum-based first-line chemotherapy. For these patients, there was a significant difference in PFS1 between the ACEI/ARB group and the non-ACEI/ARB group (\( p = 0.036 \), Fig. 4B). Recipients of either ACEIs or ARBs had a median PFS1 that was 2.1 months longer than that of non-recipients in our Kaplan-Meier analysis (7.3 vs. 5.2 months, \( p = 0.036 \), log-rank test). There was no significant difference in OS between the two groups (Fig. 4A).

For the 82 advanced NSCLC patients with hypertension, there was no significant difference in PFS1 or OS between those taking ACEIs/ARBs and those taking other antihypertensive drugs (Fig. 4C,D).

Discussion
This retrospective study is the first analysis to reveal the role of RAS inhibition on the outcomes of NSCLC patients with hypertension who took TKIs. We found that the PFS was 3.2 months longer for these patients than for those in the control group, but OS was not prolonged. Our study also observed, for the first time, the effects of ACEIs or ARBs on an Asian population of patients with advanced NSCLC who underwent surgery. The distribution of established major risk factors (age, sex, histology, stage, and performance status) in both groups was comparable.

Table 2. Number of patients receiving antihypertensive drugs

| Antihypertensive agent | Patients, n |
|------------------------|-----------|
| ACEIs/ARBs             | 52        |
| Calcium channel blockers | 40       |
| β-blockers             | 4         |
| Other drugs            | 7         |
Figure 2. Kaplan-Meier curves for OS (A) and PFS (B) with TKIs; ACEI/ARB group compared with the non-ACEI/ARB group.

Figure 3. Kaplan-Meier curves for OS (A) and PFS1 (B) in patients who underwent surgery; ACEI/ARB group compared with the non-ACEI/ARB group. Kaplan-Meier curves for OS (C) and PFS1 (D) of patients taking ACEIs/ARBs compared with those taking other antihypertensive drugs.
Both in vitro and in vivo studies have shown that ACEIs and ARBs can suppress cell proliferation and tumor metastatic growth in various cancers, including breast cancer, lung cancer, and prostate cancer. Angiogenesis appears to be an important process through which the RAS system exerts pro-tumorigenic effects, and ACEIs and ARBs reduced the expression of VEGF and other angiogenic factors in cell lines and in animal models. Components of the RAS are expressed at various cancer sites and might contribute to processes that are important for cancer progression, including cell proliferation and apoptosis. The binding of angiotensin II to its type 1 receptor activates the mitogen-activated protein kinase/signal transducer and activator of transcription (MAPK/STAT) pathway, which plays a role in the responses to many growth factors that regulate cell proliferation, differentiation and apoptosis. It has been reported that EGFR is transactivated by AT1R and transinactivated by the type 2 receptor (AT2R). Epidermal growth factor (EGF), among other things, exerts its effects by activating the MAPK/STAT pathway, leading to the development of anti-EGFR drugs as a powerful strategy for anticancer therapy. It has been reported that the activation of similar downstream effectors can directly transactivate EGFR induced by stimulation of AT1R. Our study is the first report that the PFS of NSCLC patients taking TKIs and ACEIs might be prolonged.

In all of the patients studied, there was a significant difference in PFS, but not in OS, between the ACEI/ARB group and the non-ACEI/ARB group. For the advanced NSCLC patients, the use of ACEIs or ARBs was associated with a longer PFS, regardless of whether they had hypertension. However, compared with the use of other hypertension drugs, the use of ACEIs or ARBs did not improve the PFS or OS of advanced NSCLC patients. Our findings revealed that inhibition of the RAS in human NSCLC might improve PFS, but there was little influence on OS. A favorable impact of RAS inhibition on clinical outcomes has also been reported in advanced pancreatic cancer. Previous studies have shown that long-term use of lisinopril is associated with decreased NSCLC metastasis. Two studies reported 44% and 48% reductions in the risk of overall mortality with ACEIs and ARBs,
respectively. In retrospective cohort studies of pancreatic cancer and advanced NSCLC, ACEIs and ARBs were statistically associated with longer patient survival when used with standard first-line chemotherapy. However, we did not find a significant difference in OS for all patients or for the advanced NSCLC patients taking ACEIs/ARBs, although these drugs may prolong PFS. Differences in patient race and the number of patients in our study might have caused discrepant results compared with those of previous studies.

In the patients with hypertension and early NSCLC who underwent surgery, the use of ACEIs or ARBs as opposed to other antihypertensive drugs (calcium channel blockers, β-blockers and other drugs) was associated with a longer OS, although there was no difference in PFS. Similar data have not been previously reported.

This study had some limitations, including the retrospective and non-randomized nature of the review. Furthermore, our study did not consider other important issues, such as toxicity profiles, treatment compliance, or quality of life. The number of patients in our study was limited; therefore, larger-scale research is necessary for further verification.

Conclusion

Despite the limitations of this study, this is the first report that ACEIs/ARBs increased the PFS of patients with NSCLC who received TKIs. Our clinical observations also revealed that ACEIs/ARBs had positive effects on PFS and OS, regardless of whether the lung cancer was in the early or advanced stage. A prospective study with a larger population is warranted to confirm our hypothesis.

References

1. Lever, A. F. et al. Inhibitors of angiotensin I-converting enzyme protect against risk of cancer. Lancet. 352, 179–184 (1998).
2. Friis, S. et al. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer. 92, 2462–2470 (2001).
3. Meier, C. R., Derby, L. E., Jick, S. S. & Jick, H. Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med. 160, 349–355 (2000).
4. Lindholm, L. H. et al. Relation between drug treatment and cancer in hypertensives in the Swedish trial in old patients with hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet. 358, 344–359 (2001).
5. Pasternak, B., Svanstro¨m, M., Calle’s, U., Melbye, M. & Hvidt, A. Use of angiotensin receptor blockers and the risk of cancer. Circulation. 123, 1729–1736 (2011).
6. Chang, C. H., Lin, J. W., Wu, L. C. & Lai, M. S. Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. J Clin Oncol. 29, 3001–3007 (2011).
7. Coleman, C. I., Baker, W. L., Kluger, J. & White, C. M. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. J Hum Hypertens. 26, 622–629 (2008).
8. Sipahi, I., Debanne, S. M., Rowland, D. Y., Simon, D. I. & Fang, J. C. Angiotensin-receptor blocker and risk of cancer: meta-analysis of randomized controlled trials. Lancet Oncol. 11, 627–636 (2010).
9. Ager, E. L., Neo, J. & Christophi, C. The renin-angiotensin system and malignancy. Carcinogenesis. 29, 1675–1684 (2008).
10. Khakoo, A. Y., Sidman, R. L., Pasqualini, R. & Arap, W. Does the renin-angiotensin system participate in regulation of human vasculosclerosis and angiogenesis? Cancer Res. 68, 9112–9115 (2008).
11. Greco, S. et al. Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. J Cell Physiol. 196, 370–377 (2003).
12. Egan, K. et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest. 112, 67–75 (2003).
13. Fujita, M., Hayashi, I., Yamashita, S., Imano, M. & Majima, M. Blockade of angiotensin AT1A receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res. 294, 441–447 (2002).
14. Neo, J. H., Malcontenti-Wilson, C., Muralidharan, V. & Christophi, C. Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. J Gastroenterol Hepatol. 22, 577–584 (2007).
15. Feng, Y. et al. Overexpression of ACE2 produces antitumor effects via inhibition of angiogenesis and tumor cell invasion in vivo and in vitro. Oncol Rep. 26, 1157–1164 (2011).
16. Seung, T. K. et al. How Does Inhibition of the Renin-Angiotensin System Affect the Prognosis of Advanced Gastric Cancer Patients Receiving Platinum-Based Chemotherapy? Oncology. 83, 354–360 (2012).
17. Ganz, P. A., Habel, L. A., Weltzien, E. K., Caan, B. J. & Cole, S. W. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat. 129, 549–556 (2011).
18. Heinzinger, J. H., Anthony, T., Livingston, E. H. & Huerta, S. Predictors of distant metastasis and mortality in patients with stage II colorectal cancer. Am Surg. 73, 230–238 (2007).
19. Ronquist, G., Fritzh, G., Wang, Y. & Lindeborg, T. Captopril may reduce biochemical (prostate-specific antigen) failure following radical prostatectomy for clinically localized prostate cancer. Scand J Urol Nephrol. 43, 32–36 (2009).
20. Chen, X. et al. Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer. Cancer Lett. 328, 318–324 (2013).
21. Wang, L. et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on lymphangiogenesis of gastric cancer in a nude mouse model. Chin Med J (Engl). 121, 2167–2171 (2008).
22. Deshayes, F. & Nahmias, C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab. 16, 293–299 (2005).
23. Uemura, H. et al. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther. 2, 1139–1147 (2003).
24. Cardillo, F. & Tortora, G. EGFR antagonists in cancer treatment. N Engl J Med. 358, 1160–1174 (2008).
25. Greco, S. et al. Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. J Cell Physiol. 196, 370–377 (2003).
26. Nakai, Y. et al. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer. 103, 1644–1648 (2010).
27. Kedika, R. et al. Long-term use of angiotensin converting enzyme inhibitors is associated with decreased incidence of advanced adenomatous colon polyps. J Clin Gastroenterol. 45, e12–e16 (2011).
28. Nakai, Y. et al. Inhibition of renin–angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer. 103, 1644–1648 (2011).
29. Wilpop, S. et al. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line Platinum-based chemotherapy. J Cancer Res Clin Oncol. 135, 1435–1441 (2009).
30. Nakai, Y. et al. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer. 103, 1644–1648 (2010).
Acknowledgements
This study was supported by the National Natural Science Foundation of China (81201837, 81370130).

Author Contributions
Conception and design of the experiments: Y.F. and H.Y.W.; execution of the experiments: L.L.M. and W.C.; analysis of the data: Y.F. and B.L.G.; composition of the manuscript: L.Z. and L.L.M.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Miao, L. et al. Impact of Angiotensin I-converting Enzyme Inhibitors and Angiotensin II Type-1 Receptor Blockers on Survival of Patients with NSCLC. Sci. Rep. 6, 21359; doi: 10.1038/srep21359 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/